(Q38936534)

English

A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

measles vaccine

1 reference

based on heuristic

inferred from title

author name string

Sophie Chabot

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Angela Brewer

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

George Lowell

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Martin Plante

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sonya Cyr

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

David S Burt

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Brian J Ward

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1374-1383

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Measles Virus 1998–2002: Progress and Controversy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Experimental vaccines against measles in a world of changing epidemiology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Taking toll: lipid A mimetics as adjuvants and immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Neutralizing B cell response in measles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Measles antibody: reevaluation of protective titers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Growth phase of orally administered Lactobacillus strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

The Role of Mucosal Immunity in Prevention of HIV Transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Adeno-associated virus type 2 Rep78 inhibition of PKA and PRKX: fine mapping and analysis of mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Interaction of antigens and antibodies at mucosal surfaces

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Cell-mediated immunity to respiratory virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Additional evidence that the cell-associated immune system is the primary host defense against measles (rubeola)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Inhibition of major histocompatibility complex class II-dependent antigen presentation by neutralization of gamma interferon leads to breakdown of resistance against measles virus-induced encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Infection-Triggered Regulatory Mechanisms Override the Role of STAT 4 in Control of the Immune Response to Influenza Virus Antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Differential Effects of Priming with DNA Vaccines Encoding the Hemagglutinin and/or Fusion Proteins on Cytokine Responses after Measles Virus Challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Cytokine responses during mucosal infections: role in disease pathogenesis and host defence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2004.09.010

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38936534&oldid=1797344190"